ライフサイエンスコーパス: RNA level

1 genes (DNA level) or trans-splicing events (RNA level).

2 by reprogramming genetic information at the RNA level.

3 ter or higher and an undetectable plasma HIV RNA level.

4 el, HIV infection, CD4 cell count, and HIV-1 RNA level.

5 suggesting a fairly broad expression at the RNA level.

6 not significantly contribute to the HIV gag RNA level.

7 expression in the wounds was assessed at the RNA level.

8 bundant at the protein level, but not at the RNA level.

9 chemistry to modulate gene expression at the RNA level.

10 ifies genomically encoded nucleotides at the RNA level.

11 ed differences among HIV-infected persons by RNA level.

12 effectors of SIE at the protein but not the RNA level.

13 mice and corresponded to a decrease in hGH1 RNA levels.

14 weeks; P = .008) due to lower baseline HIV-1 RNA levels.

15 semen and blood samples were assayed for HCV RNA levels.

16 mulative up-regulation of target protein and RNA levels.

17 vealed that SRSF1 did not affect oncoprotein RNA levels.

18 retroviral therapy or to have suppressed HIV RNA levels.

19 among different drugs and related to CSF HIV RNA levels.

20 els, more advanced WHO stage, and higher HIV RNA levels.

21 ith resistant tumors at both the protein and RNA levels.

22 taining CARD domain (Asc) at the protein and RNA levels.

23 of proinflammatory cytokines, and plasma SIV RNA levels.

24 nts' monocytes were directly correlated with RNA levels.

25 leus of the stria terminalis c-Fos messenger RNA levels.

26 20+ cell subsets and then analyzed for HML-2 RNA levels.

27 rexpression was observed at both protein and RNA levels.

28 n Wnt8a and decreases in Gli2, Gli3, and Shh RNA levels.

29 tissue displayed increased TANGO1 messenger RNA levels.

30 strongly correlate with each other and with RNA levels.

31 40) promoter and globally decreased cellular RNA levels.

32 ral therapy (ART) and suppressed blood HIV-1 RNA levels.

33 ent of JAG1 without affecting Jag1 messenger RNA levels.

34 d had lower HIV RNA levels (median log10 HIV RNA level, 1.59 vs 4.08 and 3.83, respectively; P < .01)

35 s for at least 6 months and had plasma HIV-1 RNA levels 1000-200 000 copies/mL.

36 The plasma HIV-1 RNA level 12 weeks after treatment interruption was comp

37 proportion of patients with undetectable HCV-RNA levels 12 weeks after therapy completion (SVR12).

38 HIV RNA levels 51-1000 copies/mL were less frequently observ

39 Three patients had undetectable HCV RNA levels 76 weeks after a single dose of RG-101.

40 of Mcl-1 expression at both the protein and RNA levels, along with a subsequent increase in apoptosi

41 Hepatitis E virus RNA levels also remained detectable in the serum and sto

42 human immunodeficiency virus type 1 : HIV-1) RNA levels among HIV-positive patients in care.

43 ur study showed that the cell-associated HIV RNA level and CD4(+) T-cell activation decreased in the

44 eased hematopoietic factors at the messenger RNA level and decreased secretion of factors at the prot

45 This study aimed to determine whether HCV RNA level and genotype affect the risk of developing ESR

46 Lower intrahepatic HBV pregenomic RNA levels and 25 predictive genes were identified in IF

47 s.com) was developed that permits queries of RNA levels and associations among RNA, platelet aggregat

48 lation was found between plasma FasL and HIV RNA levels and between Fas expression on mB cells and pl

49 Ad.IL-6 increased hepatic hepcidin messenger RNA levels and decreased serum iron concentrations in Al

50 HIV infection raises plasma HCV RNA levels and diminishes the response to exogenous alph

51 related with adipose interleukin-6 messenger RNA levels and fat mass (p < 0.001; R = 0.64 and 0.89).

52 as measured by both steady-state and nascent RNA levels and perturbed embryonic stem cell differentia

53 The effects of CDK9 inhibition on RNA levels and protein expression, apoptosis induction,

54 striking changes in QKI-dependent messenger RNA levels and splicing of RNA transcripts.

55 inactive RNase L mutant (R667A), reduced L1 RNA levels and subsequent expression of the L1-encoded p

56 We show that whereas PIGM messenger RNA levels and surface GPI expression in IGD B cells are

57 ART is associated with lower post-IFN HCV RNA levels and that change is linked to reduced hepatic

58 erve any correlation between PMP22 messenger RNA levels and the different clinical and electrophysiol

59 ate local human immunodeficiency virus (HIV) RNA levels and the risk of sexual HIV transmission.

60 henyl) retinamide (4-MPR) could reduce viral RNA levels and titers when applied to an established inf

61 ween plasma and CSF, lower overall CSF HIV-1 RNA level, and longer ART duration, among others (model

62 cell reprogramming, globally increases m(6)A RNA levels, and enhances m(6)A modification of the Nanog

63 sion molecules, chemokine/chemokine receptor RNA levels, and infiltration of leukocytes including mac

64 characteristics, including gender, age, HCV-RNA levels, and interleukin-28B genotype, did not impact

65 ctoderm progenitor cells increased lncRHOXF1 RNA levels, and siRNA-mediated disruption of lncRHOXF1 d

66 atic than those at the protein and messenger RNA levels, and suggest potential drug targets within th

67 popolysaccharide (LPS) levels, to plasma HIV RNA levels, and to memory CD8+ T cell cycling and was in

68 fection, with higher DNA and cell-associated RNA levels, and with lower expression of multiple anti-H

69 ariables (nadir/entry CD4(+) cell count, HIV RNA level, antiretroviral therapy regimen) were investig

70 Mutant ABCA4 RNA levels approximated WT ABCA4 RNA levels but, surpris

71 biogenesis, we found that Laccase2 circular RNA levels are not controlled by Mbl or the Laccase2 gen

72 m subunits, although corresponding messenger RNA levels are unaffected, whereas translational capacit

73 phila syt genes, only syt-alpha and syt-beta RNA levels are upregulated by DIMM overexpression.

74 o not, in general, correlate well, messenger RNA levels are used as convenient proxies for protein le

75 sponse, defined as an undetectable serum HEV RNA level at least 6 months after cessation of ribavirin

76 transplantation among patients with this HCV-RNA level at their last measurement before transplantati

77 f peginterferon + ribavirin dependent on HCV RNA level at week 12; (2) Harvoni treatment, 12 weeks; (

78 We evaluated the predictive ability of HCV RNA levels at end of treatment (EOT) for sustained virol

79 The decline of HBV RNA levels at months 3 and 6 of treatment was to be the

80 The fifth patient had undetectable HCV-RNA levels at the end of triple therapy but subsequently

81 This readout is highly sensitive to small RNA levels at the source, allowing plasticity in the pos

82 ften does not correlate with EGFR protein or RNA levels because they do not reflect delivery to the c

83 he primary efficacy end point was SVR12 (HCV RNA level below the lower limit of quantification at pos

84 tic patients, respectively, had baseline HCV RNA levels below 4M and 6M IU/mL with ART.

85 ed virological response (SVR)-defined as HCV RNA levels below a designated threshold of quantificatio

86 Sixty-three percent had HCV RNA levels below the lower limit of quantification at we

87 utant ABCA4 RNA levels approximated WT ABCA4 RNA levels but, surprisingly, only trace amounts of muta

88 LA-C expression is modulated not just at the RNA level, but also at the protein level.

89 Adjustment for latest HIV RNA level, but not for CD4 cell count or cancer risk fac

90 primary T-ALL cases with high GLI1 messenger RNA levels, but not those with low or undetectable GLI1

91 xide and itraconazole reduced GLI1 messenger RNA levels by 75% from baseline (P < .001).

92 We show that miR-122 enhances HCV RNA levels by altering the fraction of HCV genomes avail

93 imbalance is achieved through rescue of MRP RNA levels by ectopic expression.

94 human immunodeficiency virus type 1 (HIV-1) RNA levels by means of single-copy assay in 334 particip

95 sequence of this precise regulation of viral RNA levels by PGC1alpha is a subtle increase in cytoplas

96 Qk translation confirms that Qk5 controls Qk RNA levels by promoting accumulation and alternative spl

97 change in patients who had undetectable HCV RNA levels by week 8 post-RG-101 injection.

98 o their capsid protein genes, namely, at the RNA level, by regulating the essential splicing of an in

99 We compared HIV RNA levels, CD4 counts and percentages, lipids, and grow

100 ding was not significantly influenced by HIV RNA levels, CD4+ cell counts, or antiretroviral therapy.

101 CA, and iSCA detected 3-fold or higher HIV-1 RNA levels compared to gSCA in 10 of 25 samples.

102 polyamide demonstrated a global decrease in RNA levels consistent with inhibition of transcription.

103 Elevated seminal HCV RNA levels could contribute to sexual transmission of HC

104 evels; downregulated interleukin-6 messenger RNA levels; decreased the expression of profibrotic mark

105 Analyses of proviral and viral RNA levels demonstrate that PLVA fitness is severely res

106 erized a novel splicing site mutation at the RNA level, demonstrating that the mutant LCA5 transcript

107 t protein tyrosine kinase 2 (PTK2) messenger RNA levels derived greater benefit from R-FC, with signi

108 RNA levels detected at steady state are the consequence

109 The index patient had high EBOV RNA levels, developed respiratory and renal failure requ

110 Despite having undetectable HIV RNA levels during cART, men with higher concentrations o

111 sed claudin-7 mRNA and nascent heteronuclear RNA levels during differentiation.

112 ular interactions, both at the chromatin and RNA level, exhibit remarkable specificity for the regula

113 On the RNA level, expanded (CUG)n repeats form hairpin structur

114 model that incorporates these protein/DNA or RNA level fluctuations can effectively predict antigenic

115 ns and PARN-depleted cells exhibited reduced RNA levels for several key genes that are associated wit

116 We found moderate heterogeneity between HCV RNA levels from different intrahepatic sites, indicating

117 adioactive enzyme assays, and CD73 messenger RNA levels from leukocytes using quantitative polymerase

118 FT messenger RNA levels generally correlate with flowering time among

119 gene copy number is altered experimentally, RNA levels generally scale accordingly.

120 ologic failure, defined as a confirmed HIV-1 RNA level greater than 1000 copies/mL at or after 16 wee

121 h specificity, and good correlation with HCV RNA levels greater than 3000 IU/mL and have the potentia

122 RCHITECT, HCVcAg correlated closely with HCV RNA levels greater than 3000 IU/mL.

123 Patients with HCV-RNA levels >/= 12 IU ml-1 after 4 weeks of treatment ach

124 lure (VF) was defined as 2 consecutive HIV-1 RNA levels >/=200 copies/mL at least 12 weeks after salv

125 er, 32 genes differentially expressed at the RNA level had concomitant differential expression of the

126 Adjustment for latest HIV RNA level had little impact on the protective effect of

127 -MB-231, which has the highest xCT messenger RNA level, had the highest tracer uptake (P = 0.0058 whe

128 >/=6 months before screening) and plasma HCV RNA levels higher than 10,000 IU/mL.

129 ART was predicted by a higher pre-ART HIV-1 RNA level, higher CD8(+) T-cell count during treatment,

130 he collective impact of source partner HIV-1 RNA levels, human leukocyte antigen (HLA) alleles, and i

131 also replicated acutely to high peak plasma RNA levels identical to those for SIVmac239 and caused o

132 d cells increased both cyclin B1 protein and RNA levels, implicating FoxM1 as a critical target for c

133 Results were validated at the RNA level in an independent cohort and at the protein le

134 cute HCV and HIV coinfection, the median HCV RNA level in blood specimens from those with seminal HCV

135 The median HCV RNA level in blood was 4.0 log IU/mL higher than that in

136 We further demonstrate that MYCN messenger RNA levels in amplified disease are exceptionally high a

137 Ebola viral RNA levels in blood peaked at a median of 7 days after t

138 Using a single-copy assay, we measured HIV-1 RNA levels in CSF and plasma specimens from 220 HIV-posi

139 The relationship between HAND, lower HIV-1 RNA levels in CSF, and lower CD4(+) T-cell counts may re

140 Next, we found that PPM1F messenger RNA levels in human blood were downregulated in cases wi

141 TNF, IL-6, IL-1beta, and IFN-gamma messenger RNA levels in pancreatic tissue.

142 kidney allograft by measuring HIV-1 DNA and RNA levels in patients' urine.

143 essed in the context of viral blips or viral RNA levels in peripheral blood or gastrointestinal biops

144 ) show increases in unspliced cellular HIV-1 RNA levels in resting CD4(+) T cells.

145 Surprisingly, the alterations in messenger RNA levels in septic cardiomyopathy were both distinct f

146 We did not find increased PMP22 messenger RNA levels in skin and sural nerve biopsies of patients

147 d in persistent SIV-RNA production while SIV-RNA levels in SM macrophage cultures decreased 10- to 10

148 Finally, we analysed PMP22 messenger RNA levels in sural nerve biopsies.

149 and more profound than changes in messenger RNA levels in the hearts of patients with end-stage hear

150 reduced Ser-235 phosphorylation and the HCV RNA levels in the infected cells.

151 effect of NPY on preproenkephalin messenger RNA levels in the striatum using fluorescent and radioac

152 The mean peak viral RNA levels in the vaccinated groups were 30-fold lower t

153 otably, correlated inversely with plasma HIV RNA levels in viremic HIV patients.

154 Correlates of higher CSF HIV-1 RNA levels included higher nadir and current CD4(+) T-ce

155 evels (by 1.98 log10 copies/mL), whereas HBV RNA levels increased (by 0.47 log10 copies/mL; P < .05).

156 ted that RTA targets MyD88 expression at the RNA level, inhibits RNA synthesis of MyD88, and may bind

157 t with simeprevir or daclatasvir reduced HCV RNA levels initially, but the levels later rebounded.

158 HRE structural polymorphism at both DNA and RNA levels initiates molecular cascades leading to ALS/F

159 ght correlation between gene copy number and RNA levels is not observed in recently isolated wild Sac

160 We show that SIRT1 protein, but not RNA levels, is overexpressed in AML samples harboring ac

161 ly virologic response (cEVR), defined as HCV-RNA level less than 10 IU/mL after 12 weeks of PEG-IFNal

162 The primary end point was an HCV-RNA level less than 25 IU/mL at 12 weeks after treatment

163 ulation consisted of 43 patients who had HCV-RNA level less than 25 IU/mL at the time of transplantat

164 acy was measured by SVR12, defined as an HCV-RNA level less than 25 IU/mL.

165 s or the proportion of participants with HIV RNA level less than 50 copies/mL.

166 Co-infected patients who maintained HIV RNA levels less than 1000 copies/mL still had higher rat

167 oint was the proportion of patients with HCV-RNA levels less than 25 IU/mL at 12 weeks after transpla

168 ighly active antiretroviral therapy with HIV RNA levels less than 400 copies/mL was associated with p

169 At 48 weeks, 90% of patients achieved HIV-1 RNA levels less than 50 copies/mL.

170 ssociated with low CD4 cell counts, high HIV RNA levels, low CD4/CD8 ratios, and prior AIDS.

171 ts with sustained viral response (plasma HCV RNA level <12 IU/mL) 12 weeks after end of treatment.

172 ltrasensitive assays on specimens with HIV-1 RNA level <400 copies/mL at weeks 24, 48, and 104 reveal

173 IV suppression status (defined as HIV type 1 RNA level <400 copies/mL for >90% of follow-up time) was

174 als were eligible if they had a plasma HIV-1 RNA level <50 copies/mL for at least 2 years on a stable

175 0 copies/mL and 10 of 11 (91%) had CSF HIV-1 RNA levels <2 copies/mL at week 16.

176 Despite years of plasma HIV-RNA levels <40 copies per milliliter during combination

177 ents with prolonged viral suppression of HIV-RNA levels <40 copies per milliliter for more than 6 y.

178 f 11 subjects (82%) had plasma and CSF HIV-1 RNA levels <50 copies/mL and 10 of 11 (91%) had CSF HIV-

179 A total of 234 participants (71%) with HIV-1 RNA levels <50 copies/mL by week 24 were included.

180 Participants with plasma HIV RNA levels <50 copies/mL during antiretroviral therapy a

181 ve, non-cirrhotic patients with baseline HCV RNA levels <6 million IU/mL (6.8 log10 IU/mL).

182 ipheral CD4+ T-cell-associated HIV-1 DNA and RNA levels, lymphocyte activation, viral population stru

183 Serum HBV RNA levels may serve as a novel tool for prediction of s

184 s, respectively; P < .01), and had lower HIV RNA levels (median log10 HIV RNA level, 1.59 vs 4.08 and

185 reduced the levels of cyclin B1 protein, and RNA levels normally increased in response to DNA-damagin

186 current CD4(+) T-cell counts, a plasma HIV-1 RNA level of >/= 1 copy/mL, and a lower central nervous

187 t was a sustained virologic response (an HCV RNA level of <25 IU per milliliter) 12 weeks after the e

188 t was a sustained virologic response (an HCV RNA level of <25 IU per milliliter) at week 12 after the

189 tiretroviral treatment, 73% had plasma a HIV RNA level of <50 copies/mL, and the median CD4(+) T-cell

190 The messenger RNA level of at least one B-subgroup ABCB gene in Arabid

191 CAMK2 (CAMKII), we examined blood messenger RNA level of CAMK2G in humans and found it to be lower i

192 ation of soluble form of CD73, and messenger RNA level of CD73 all decreased along with the disease s

193 aled a significant decrease in the messenger RNA level of early B cell factor 1 (EBF1) and paired box

194 rates of DBS in participants with plasma HIV RNA levels of >/=35 copies/ml and 100% detection rates o

195 rates of DPS in participants with plasma HIV RNA levels of >/=394 copies/ml.

196 ere observed with respect to detecting HIV-1 RNA levels of >50 copies/ml and identifying VF at the 50

197 additional participants with confirmed HIV-1 RNA levels of >50 copies/ml during trial follow-up were

198 .82), Abbott was more likely to detect HIV-1 RNA levels of >50 copies/ml than Monitor (matched-pair o

199 prior HIV diagnosis; 83 of those men had HIV RNA levels of <1000 copies/mL at enrollment.

200 ive, noncirrhotic patients with baseline HCV RNA levels of <4 or <6 million (M) IU/mL based on post-h

201 t limit of detection equivalent to serum HCV RNA levels of 150-250 IU/mL; using nondenaturation of se

202 I, 0.1 to 0.5]), but HAART in those with HIV RNA levels of 400 copies/mL or greater was not.

203 the HCV-Ags EIA were equivalent to serum HCV RNA levels of approximate 150-250 IU/mL.

204 r their association with residual cognition: RNA levels of both UNC5C (estimated effect = -0.40, 95%

205 6 can decrease T-cell surface expression and RNA levels of CD127, the interleukin 7 receptor alpha ch

206 In the presence of comparable messenger RNA levels of CD3, IL-10, TGFbeta, IL2, IFNgamma, and IL

207 RT-PCRs revealed that RNA levels of cotransfected genes were unchanged during

208 hat were associated with increased messenger RNA levels of CSF1 in the PFC.

209 om controls, and detected elevated messenger RNA levels of D2-autoreceptors and GIRK2 in Parkinson's

210 negative cells altered protein and messenger RNA levels of markers of epithelial-mesenchymal transiti

211 ndicate that the regulation of the messenger RNA levels of miRNA targets involves not just the action

212 ic antisense oligonucleotides to inhibit the RNA levels of mutant AR in the central nervous system (C

213 elevated substantia nigra dopamine messenger RNA levels of NCS-1 (but not Cav1.2 or Cav1.3) after coc

214 Transcriptome analysis shows diminished RNA levels of numerous genes in Nfatc1 (-/-) CD8(+) T ce

215 s, Malanchi and colleagues analyze messenger RNA levels of periostin (POSTN) in pulmonary fibroblasts

216 ued the anxiety-like phenotype and messenger RNA levels of Ppm1f in amygdala and mPFC in male mice an

217 We also measured messenger RNA levels of SIRT1, SFRS10, and lipin-1beta and lipin-1

218 Messenger RNA levels of specific M1 and M2 markers were measured b

219 primary outcome was the change in messenger RNA levels of the GLI family zinc finger 1 (GLI1) gene (

220 ed for age, sexual behaviour, and plasma HIV RNA levels of the HIV-infected partner.

221 Messenger RNA levels of the master lytic regulatory EBV gene BZLF1

222 administration of AM1710 decreased messenger RNA levels of tumor necrosis factor-alpha and monocyte c

223 ily on the degree of association between the RNA levels of two genes and to a lesser extent on their

224 a1 increased the protein expression, but not RNA levels, of both DNMT1 and DNMT3a.

225 er EREG or AREG in top tertile for messenger RNA level) or "low expressor" (neither EREG nor AREG in

226 unt, previous response to HCV treatment, HCV RNA level, or HCV RNA decline at week 4.

227 Cell-associated HIV RNA levels (P=.035), RNA to DNA transcriptional ratios (

228 negative correlation between DDX5 messenger RNA levels, pluripotency gene expression, and liver tumo

229 s of transcriptome-wide changes in messenger RNA levels provoked by various types of oxidative stress

230 negative specimens as HIV RNA positive, with RNA levels ranging from 300 to >10,000,000 copies/ml.

231 endent approaches by monitoring steady-state RNA levels, rates of RNA synthesis, transcription initia

232 knockdown (80% at the protein and messenger RNA levels) reduced by 30% cytokine-induced apoptosis an

233 HIV-RNA levels remained controlled and CD4 cell counts remai

234 -term NA treatment of patients with CHB, HBV RNA levels remained higher than HBV DNA levels.

235 However, the RALY's role in regulating RNA levels remains elusive.

236 Clinical recovery, EBOV RNA level, resolution of Ebola viremia, survival with di

237 mimic and inhibitor of DENV-vsRNA-5 on DENV RNA levels revealed DENV-vsRNA-5's role in virus autoreg

238 study, we aimed to assess the effect on HDV RNA levels, safety, and tolerability of the prenylation

239 or absence of HCV RNA or changes in the HCV RNA level should be taken into consideration for therapy

240 ere positively associated with pre-ART HIV-1 RNA levels (Spearman = 0.71, P < .001) and with HIV-1 DN

241 3L rescues the effect of PARN depletion on Y RNA levels, suggesting that PARN stabilizes Y RNAs by re

242 itis elegans results in changes in messenger RNA levels that last for more than one generation.

243 reliable indicator of variations in cellular RNA levels, that better correlates with cellular metabol

244 d a consistent (but small) increase in viral RNA levels, the drb4 mutant correlated with a less prono

245 Next, from single-cell, single-RNA level time-lapse microscopy of independent lineages

246 ctors contributing to the fast adaptation of RNA levels to different environmental demands.

247 Although variation in RNA levels, transcription factor binding, and chromatin

248 While F9 is fused to Alb at the DNA and RNA levels, two separate proteins are synthesized by way

249 HBV RNA levels vary significantly from those of established

250 Furthermore, HIF-1alpha messenger RNA levels vary significantly within CLL patients and co

251 F expression is known to be regulated at the RNA level, very little is known about the mechanisms inv

252 A high delivery maternal plasma HIV-1 RNA level (viral load [VL]) is a risk factor for mother-

253 aseline human immunodeficiency virus (HIV)-1 RNA level (VL), CD4 cell counts (CD4), subtype, and trea

254 kPa; cirrhosis, n = 9); median baseline HCV-RNA level was 1.38 x 10(6) IU/mL.

255 gative patients, a lower baseline plasma HBV RNA level was independently associated with response to

256 Peak HCV RNA level was lower during reinfection than primary infe

257 viduals, continued decay of the plasma HIV-1 RNA level was observed, with an average annual decrease

258 A corresponding decrease in NPPA messenger RNA levels was also observed at both time points.

259 A similar decline in HBV RNA levels was observed in HBeAg-negative patients.

260 HIV serostatus and plasma HIV RNA level were measured annually at multidisease health

261 Reduction of endogenous ATXN1 messenger RNA levels were >/=30% in the deep cerebellar nuclei, th

262 (n = 20) HIV infection were studied once HIV RNA levels were <50 copies/mL for >/= 6 months.

263 Increased CSF1 messenger RNA levels were also detected in the postmortem dorsolat

264 Higher baseline HIV-1 RNA levels were associated with greater gains in periphe

265 Higher HIV RNA levels were associated with higher IL-6 levels, and

266 Patients with low and high HCV RNA levels were at higher risk of ESRD than those who we

267 Viral RNA levels were below limits of detection during all oth

268 HCV RNA levels were correlated in semen and blood (r(2) = 0.

269 MicroRNA and messenger RNA levels were determined by quantitative real-time pol

270 HCV RNA levels were determined by real-time polymerase chain

271 The PBMCs alpha7 messenger RNA levels were determined by real-time quantitative rev

272 HBV RNA levels were determined in serial serum samples from

273 vated protein kinase phosphatase-1 messenger RNA levels were down-regulated.

274 By 14 days p.i., spliced SIV RNA levels were high in all tissues, but they were the h

275 ydroxylated bile acids and Cyp3a11 messenger RNA levels were higher in NHERF-1(-/-) BDL mice.

276 Hdac4 messenger RNA levels were higher in the amygdala 2 h after tone-sh

277 SNV RNA levels were higher in the lungs but not different in

278 In 64 patients, HCV-RNA levels were less than 25 IU/mL by week 4 of treatmen

279 The HIV-1 RNA levels were measured in CSF at baseline and weeks 2

280 Finally, higher tissue factor messenger RNA levels were measured in the whole blood of 131RR don

281 riants of PPARGC1A and protein and messenger RNA levels were measured.

282 ymptoms and developed moderate illness; EBOV RNA levels were moderate, and both patients recovered.

283 The decreases in occupancy and RNA levels were not seen, however, during the dark (acti

284 Plasma HIV-1 RNA levels were not significantly lower in early-treated

285 beta-mediated antiviral state, ExoN(-) viral RNA levels were not substantially reduced relative to th

286 or-beta, but not -alpha intragraft messenger RNA levels were reduced and capillary protein localizati

287 e type I interferon (IFN-I) response, as VA1 RNA levels were reduced by pretreatment of Caco-2 cells

288 In contrast, CDC42 and PAK1 messenger RNA levels were significantly downregulated specifically

289 HCV RNA levels were significantly higher with CAP/CTM than w

290 4, LIMK1, LIMK2, ARHGDIA, and PAK3 messenger RNA levels were significantly upregulated in subjects wi

291 cleavage/polyadenylation machinery, circular RNA levels were similarly increased.

292 CA HIV-1 DNA and RNA levels were strongly correlated (r= 0.77 to 1;P= 0.0

293 of patients with active replication, but HCV RNA levels were substantially lower than in serum specim

294 t 7 days postinoculation (p.i.), spliced SIV RNA levels were the highest in the genital lymph nodes,

295 reating genetic disease, particularly at the RNA level, where disease-relevant sequences can be rescu

296 nother layer of epigenetic regulation at the RNA level, where mRNA is subjected to chemical modificat

297 NA levels and HIV DNA decay and cellular HIV RNA levels, while adjusting for peak HIV RNA, nadir CD4(

298 o pre-mRNA by splicing factors to act at the RNA level with KAT2B and other KATs to catalyze dynamic

299 enabled the analysis of cellular protein and RNA levels with unprecedented depth and sensitivity, all

300 act as potent regulators of translation and RNA levels, with a similar magnitude to miRNAs.